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QuercetinThe studywas designed to investigate the beneﬁcial effect of quercetin supplementation in 3-nitropropionic acid
(3-NP) induced model of Huntington's disease (HD). HDwas induced in rats by administering sub-chronic dose
of 3-NP, intraperitoneally, twice daily for 17 days. Quercetin was supplemented at a dose of 25 mg/kg body
weight by oral gavage for 21 days. At the end of treatment, mitochondrial bioenergetics, mitochondrial swelling,
oxidative stress, neurobehavioral deﬁcits and histopathological changes were analyzed. Quercetin supplementa-
tion was able to reverse 3-NP induced inhibition of respiratory chain complexes, restore ATP levels, attenuate
mitochondrial oxidative stress in terms of lipid peroxidation and prevent mitochondrial swelling. Quercetin
administration also restored the activities of superoxide dismutase and catalase along with thiol content in
3-NP treated animals. Beneﬁcial effect of quercetin administration was observed on 3-NP inducedmotor deﬁcits
analyzed by narrow beam walk and footprint analysis. Histopathological analysis of 3-NP treated rats revealed
pyknotic nuclei and astrogliosis in striatum, which were reduced or absent in quercetin supplemented animals.
Altogether, our results show that quercetin supplementation to 3-NP induced HD animals ameliorated mito-
chondrial dysfunctions, oxidative stress and neurobehavioral deﬁcits in rats showing potential of this ﬂavonoid
in maintaining mitochondrial functions, suggesting a putative role of quercetin in HD management.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Huntington's disease (HD) is a progressive, fatal, neurodegenerative
disorder caused by an expanded CAG repeat in the huntingtin gene
(Htt), that encodes for an abnormally long polyglutamine tract in a
protein termed huntingtin (htt) with a molecular weight of approxi-
mately 350 kDa [1]. The disease is inherited in an autosomal dominant
mannerwith age-dependent penetrance. Clinical features of HD include
progressive motor dysfunctions, cognitive decline, and psychiatric
disturbances, including both neuronal dysfunctions and neuronal cell
death [2]. Although, mutation in Htt gene was discovered more than
17 years ago, the role of Htt in the physiology and the pathophysiol-
ogy is still under investigation [3]. Recent data indicates that the trans-
location of mHtt into nucleus and transcriptional dysregulation likely
play an important role in the pathogenic process and more speciﬁcally
these events have a signiﬁcant impact on mitochondrial functions
such as electron transport chain (ETC) and reactive oxygen species
(ROS) generation leading to bioenergetic failure [4]. Numerous studiescatalase; DTNB, 5,5-dithiobis-
untington's disease; LMW-SH,
BT, nitroblue tetrazolium; PSH,
en species; SOD, superoxide
ls
, PanjabUniversity, Chandigarh,
rights reserved.in cell and mouse models of HD have revealed mitochondrial impair-
ment [5].
The hypothesis that mitochondrial dysfunctions contribute to
the pathogenesis of HD was ﬁrst tested pharmacologically by using
3-nitropropionic acid (3-NP), an irreversible inhibitor of succinate de-
hydrogenase [6]. One of themechanisms following 3-NP administration
is the development ofmitochondrial dysfunctions leading to generation
of a bioenergetic defect which involves three interacting processes such
as: energy impairment, oxidative stress and excitotoxicity [7]. 3-NP
induced HD model replicates most of the clinical and pathophysiologi-
cal hallmarks of HD, including spontaneous choreiform and dystonic
movements, frontal-type cognitive deﬁcits, and progressive striatal
neuronal degeneration [8]. 3-NP administration also results in ATP
depletion, which impairs intracellular calcium buffering thereby
leading to production of damaging ROS [9].
At present, there are no effective treatments against HD. Current
therapies for treating HD are symptomatic; focusing on neurological
and psychiatric symptoms that aim at improving the quality of life
[10]. Attention has been given on the inﬂuence of phytochemical
therapeutics on health and mental well-being. Evidence has indicated
that a group of plant-derived compounds known as ﬂavonoids exerts
particularly powerful action as cardioprotective, chemopreventive
and neuroprotective agents [11]. The biological activities of ﬂavo-
noids have been attributed to their antioxidant, anti-inﬂammatory
and their property to modulate signaling cascades [12]. Within the
ﬂavonoid family, quercetin is the most potent scavenger of ROS and
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ence of two antioxidant pharmacophores within the molecule that
have the optimal conﬁguration for free radical scavenging [13]. Querce-
tin has been shown to easily traverse the blood–brain-barrier and acts
as promising agents for intervention in neurodegenerative conditions
like ischemia [14], Alzheimer's disease [15] and Parkinson's disease
[16]. Use of neuroprotective antioxidants is being considered as a prom-
ising approach to slow down the disease progression and to limit the
extent of functional neuronal loss in chronic neurodegeneration as
well as after acute lesions of the brain. However, only a few studies on
the use of antioxidants in themanagement of neurodegenerative condi-
tions have so far been undertaken.Methodological inconsistencies, poor
permeation of the blood–brain barrier and lower efﬁcacy per dose are
some reasons for the lack of studies in this area [17]. Quercetin exerts
its beneﬁcial effect in brain primarily through its antioxidant action.
Quercetin has been shown to improve mitochondrial functions in
brain by increasingmitochondrial biogenesis [18]. Within the subcellu-
lar compartment quercetin shows preferential accumulation in mito-
chondria [19]. Based on the information in the literature, quercetin
appears to be promising agent against HD. Therefore, in the present
study, we have evaluated the neuroprotective potential of quercetin
against 3-NP induced mitochondrial oxidative stress, mitochondrial
dysfunctions and neurobehavioral deﬁcits.
2. Experimental procedures
2.1. Chemicals
All the chemicals used in the present study were of analytical grade
and were purchased from Sigma Chemical Co. (St. Louis, USA), Merck
(Mumbai, India) and Sisco Research Laboratories Pvt. Ltd. (Mumbai,
India). Quercetin was purchased from Himedia Laboratories Pvt. Ltd.
(Mumbai, India).
2.2. Animals and treatment schedule
Female Wistar rats aged 9–10 weeks, weighing between 200 and
250 g were procured from the Central Animal House facility of Panjab
University, Chandigarh, India. The animals were allowed to acclimatize
to the local vivarium for 7 days. All the experiments were carried out
between 09:00 and 15:00 h. The protocols followed were approved by
the Institutional Animal Ethics Committee of the University and were
in accordancewith the guidelines for humaneuse and care of laboratory
animals. The animals were randomly segregated into the following four
groups with each group having 6–8 animals.
Control (vehicle): animals were given vehicle.
Control+quercetin treated: animalswere administeredwith vehicle
for 3-NP and quercetin at a dose of 25 mg/kg through oral gavage for
21 days.
3-NP treated: animals were administered 3-NP at a sub-chronic dose
twice a day intraperitoneally for 17 days. Twice a day injections
were: 7.5 mg/kg for the ﬁrst 2 days, followed by 3.75 mg/kg for
next 7 days, ﬁnally a dosage of 2 mg/kg for the last 8 days. The
dose of 3-NP used in the study is based on the doses reported in lit-
erature and were standardized in our laboratory [20].
3-NP+quercetin treated: One hour before sub-chronic 3-NP treat-
ment, animals were administered with quercetin at a dose of
25 mg/kg by oral gavage for 21 days.
2.3. Mitochondrial respiratory chain enzymes
2.3.1. Isolation of rat brain mitochondria
On day 21, animals were sacriﬁced by decapitation under mild ether
anesthesia. Mitochondria were isolated from striatum by the methoddescribed by Puka-Sundvall [21]. Brieﬂy, corpus striatum was dissected,
rinsed in ice-cold isotonic saline and homogenized in ice-cold extraction
buffer (10 mM Tris–HCl, pH 7.4, 0.44 M sucrose, 10 mM EDTA and 0.1%
BSA). The homogenate was centrifuged at 2100 g for 15 min at 4 °C.
The pellet was discarded and the supernatant re-centrifuged at 14,000 g
for 15 min at 4 °C. The crudemitochondrial pelletwas separated, washed
with extraction buffer and centrifuged at 7000 g for 15 min at 4 °C. The
ﬁnal mitochondrial pellet was re-suspended in buffer containing 0.44 M
sucrose in 10 mM Tris–HCl, pH 7.4.
2.3.2. NADH dehydrogenase (complex I)
Activity of NADH dehydrogenase was measured as described by
King and Howard [22]. Requisite amount of mitochondrial preparation
was added to the reaction mixture containing 0.2 M glycyl-glycine
(pH 8.5), 6 mM NADH, 1 mM oxidized cytochrome c and 0.02 M
NaHCO3. NADH dehydrogenase catalyzed reduction of cytochrome c
and the increase in absorbance was followed spectrophotometrically
at 550 nm for 3 min. Results were expressed as nmol NADH oxidized/
min/mg protein. The enzyme activity was normalized to citrate
synthase activity.
2.3.3. Succinate dehydrogenase (complex II)
Activity of succinate dehydrogenase was assayed according to the
method of King et al. [23]. The reaction mixture contained 0.2 M sodi-
um phosphate buffer (pH 7.8), 1% (w/v) BSA, 0.6 M succinate and
0.03 M potassium ferricyanide. The reaction was initiated by addition
of requisite amount of mitochondrial preparation. Succinate dehydro-
genase catalyzes the oxidation of succinate to fumarate by potassium
ferricyanide, which was measured spectrophotometrically by decrease
in absorbance at 420 nm for 3 min. Results were expressed as nmol
succinate oxidized/min/mg protein. The enzyme activity was normal-
ized to citrate synthase activity.
2.3.4. Cytochrome oxidase (complex IV)
Activity of cytochrome oxidase was assayed according to the
method described by Sottocasa et al. [24]. Oxidized cytochrome c
was reduced by adding few crystals of sodium borohydride and then
neutralized to pH 7.0 by 0.1 M HCl. 0.3 mM of reduced cytochrome c
was added to 0.075 M phosphate buffer and the reaction was initiated
by mixing appropriate amount of mitochondrial suspension. The
reduced cytochrome c is oxidized in the reaction mixture containing
cytochromeoxidasewhich ismeasured spectrophotometrically by a de-
crease in absorbance at 550 nm for 3 min. Results were expressed as
nmol cytochrome c oxidized/min/mg protein. The enzyme activity
was normalized to citrate synthase activity.
2.3.5. F1F0 synthase (complex V)
Mitochondrial F1F0 synthase activity was measured as described
by Grifﬁths and Houghton [25]. Reaction was started by adding appro-
priate amount of mitochondrial suspension in ATPase buffer [50 mM
Tris and 5 mM MgCl2, pH 7.5] at 37 °C with 5 mM ATP for 10 min.
The reaction was stopped by adding 10% (w/v) trichloroacetic acid.
The contents were centrifuged at 3000 g for 20 min, and an appropriate
volume of supernatantwasmixedwithwater. Phosphate producedwas
measured by the method of Fiske and Subbarow [26]. Results were
expressed as nmol of ATP hydrolyzed/min/mg protein. The enzyme
activity was normalized to citrate synthase activity.
2.3.6. MTT reduction
The reduction of MTT to blue formazan by dehydrogenases present
in the mitochondrial suspension was also monitored to assess mito-
chondrial functions [27]. To appropriate mitochondrial pellet, MTT
(0.1 mg/ml) was added, mixed and incubated at 37 °C for 30 min and
then centrifuged to obtain formazan pellet. The pellet was dissolved in
absolute ethanol and the mixture was re-centrifuged at 2000 g for
10 min. The absorbance of the supernatant was measured at 595 nm.
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values were normalized to citrate synthase activity.
2.3.7. Citrate synthase assay
Citrate synthase (CS) was assayed as described by Coore et al. [28],
wherein the reduction of 0.2 mM 5,5′-dithio-bis(2-nitrobenzoic acid)
in the presence of 0.2 mM acetyl-CoA and 0.1 mM oxaloacetate in a
medium with 100 mM Tris–HCl, pH 8.0 and 0.1% Triton X-100 was
performed at 412 nm. The CS activity was expressed as nmol/min/mg
protein.
2.3.8. Mitochondrial swelling
Mitochondrial swelling and contraction by measurement of light
scattering in a spectrophotometer were used as a functional test of
mitochondrial membrane integrity as described by Tedeshi and
Harris [29]. This method is based upon the increased absorbance of
mitochondria in a contracted state and decreased density in a swollen
or orthodox conﬁguration due to cation inﬂux that can be detected by
measurement of light scattering at 520 nm. To appropriate mitochon-
drial suspension, 0.12 M KCl in 0.02 M Tris–HCl was added and mito-
chondrial swelling was measured at 520 nm for 6 min. Contraction of
mitochondria was initiated after 6 min by adding Mg2+-ATP. Change
in absorbance at 520 nmwas normalized by the protein concentration.
2.3.9. Adenine nucleotide levels
ATP and ADP levels were determined by the method of Victor et al.
[30]. Frozen tissues were transferred to a 1.5-ml micro-centrifuge tube
and added with 0.4 M perchloric acid. The tissue was immediately
homogenized with a pestle and the homogenate was kept on ice for
30 min, and then centrifuged at 14,000 rpm at 4 °C. The supernatant
was neutralized with 4 M K2CO3, kept on ice for 10 min and at−80 °C
to promote precipitation of the perchlorate, and then centrifuged again.
Supernatants were then stored at −80 °C until HPLC assay. Aliquots
of the extract and standard were applied separately to the column
and the eluate was monitored at 254 nm, at a ﬂow rate of 2 ml/min
using supelcosil LC-18, 5 μm (15 cm∗0.46 cm) reversed phase column
(Supelco, Crans, Switzerland). An isocratic elution of the samples
was performed with 0.52 μm potassium phosphate buffer (KH2PO4;
pH 4.0), containing 0.04% tetrabutylammonium phosphate and 1.25%
(v/v) methanol. Peaks were identiﬁed by their retention times and
by using cochromatography with standards. Results were expressed as
nmol/mg protein.
2.4. Mitochondrial oxidative stress
2.4.1. Lipid peroxidation
Malondialdehyde (MDA), a measure of lipid peroxidation was
quantiﬁed by reaction with thiobarbituric acid at 532 nm by the
method of Ohkawa et al. [31]. The values were expressed as nmol
MDA/mg protein, using molar extinction coefﬁcient of chromophore
(1.56×105M−1cm−1).
2.4.2. Superoxide dismutase (SOD)
SOD activity was assayed inmitochondrial preparation, wherein the
inhibition of nitrozo blue tetrazolium (NBT) reductionwasmeasured at
560 nm [32]. Brieﬂy, the reaction was initiated by the addition of
hydroxylamine hydrochloride to the reaction mixture containing NBT
and sample. The results were expressed as Units/mg protein, where
one unit of enzyme is deﬁned as the amount of enzyme inhibiting the
rate of reaction by 50%.
2.4.3. Catalase
Catalase (CAT) activity was assayed in mitochondrial suspension
by the method of Aebi [33]. The decomposition of hydrogen peroxide
(H2O2) by CAT was monitored spectrophotometrically by following
the decrease in absorbance at 240 nm. The activity of enzyme wasexpressed as nmol of H2O2 decomposed/min/mg protein, using molar
extinction coefﬁcient of H2O2 (71 M−1cm−1).
2.4.4. Thiols
2.4.4.1. Total thiols. Total thiols (TSH) were quantiﬁed in themitochon-
drial preparation according to the method of Sedlak and Hanus [34]. In
this method, DTNB is reduced by protein and non-protein free \SH
groups to form 1 mol of 5-mercapto-2-nitrobenzoate per mol of \SH.
Absorbance was read at 412 nm and the results were expressed as
nmol TSH/mg protein.
2.4.4.2. Low molecular weight thiols (LMW-SHs). LMW-SHs (probably
GSH) were estimated in the mitochondrial preparation by the method
of Roberts and Francetic [35]. Absorbance was measured at 412 nm
and results were expressed as nmol LMW-SH/mg protein.
2.4.4.3. Protein thiols. Levels of protein thiols (P-SHs) were calculated
from the difference between the values of total thiols and LMW-SHs
and expressed as nmol P-SH/mg protein.
2.5. Estimation of protein
The protein content was estimated according to the method of
Lowry et al. [36].
2.6. Neurobehavioral studies
2.6.1. Locomotor activity
The locomotor activity was measured using actophotometer [37].
The interruption of a beam of light falling on a photocell following
the movement of the animal was recorded. Each rat was placed indi-
vidually in the actophotometer for 3 min and numbers of counts were
recorded.
2.6.2. Narrow beam walk test
This behavioral test was used to evaluate motor performance in the
treated animals vs. the controls, by progressively increasing the difﬁcul-
ty in the execution of the task as described by Henderson et al. [38]. The
animals were trained in crossing a 150 cm long wooden beam, divided
into three 50 cm segments, from a platform at one end to the animal's
home cage at the other end, placed horizontally 60 cm above the
ﬂoor. The number of paw slips onto an under-hanging ledge and the
time taken to traverse the beam was recorded. The maximum time
allowed for the task was 2 min. Occurrence of bradykinesia was quanti-
ﬁed by calculating the average velocity of walking for treated and con-
trol animals.
2.6.3. Footprint analysis
This test was used to assess gait abnormalities in 3-NP treated an-
imals [20]. After coating the hind feet with a non-toxic green dye and
forepaws with a non-toxic red dye, rats were allowed to walk on a
beam (100 cm length, 12 cm breadth and 10 cm high walls with an
inclination of 30°) leading to a darkened enclosure. The gangway
was lined with white paper for recording the feet impressions.
Animals in all the groups were tested for footprint length, footprint
breadth, and footprint stride length for both left and right paws.
Speciﬁcally, footprint stride length was quantiﬁed as the distance
between two subsequent feet. Paws overlap analysis was carried out
by measuring the center distance between the anterior paw and
rear paw footprints.
2.7. Histochemical and histological analysis
The frozen brain sections were processed for SDH histochemical
staining [39]. Animals were anesthetized and transcardially perfused
Table 1
Effect of quercetin administration on the activity of mitochondrial complexes in striatum of 3-NP treated rats.
Complex I (nmol NADH
oxidized/min/mg protein)
Complex II (nmol succinate
oxidized/min//mg protein)
Complex IV (nmol cytochrome
C oxidized/min/mg protein)
F1F0 ATPase (nmol ATP
hydrolyzed/min//mg protein)
MTT reduction (μg formazan
formed/min/mg protein)
Control 109.23±13.32 147.61±4.54 162.58±6.08 17.69±1.69 5.46±0.2
(131.6±8.49) (177.74±4.38) (195.82±8.19) (21.22±3.78) (6.57±0.5)
Quercetin 106.9±16.19 145.9±8.42 145.57±2.77 17.45±1.2 4.56±0.38
(116.9±11.84) (159.4±14.11) (158.65±8.5) (19.0±3.55) (4.97±0.7)
3-NP 60.05±7.83⁎ 71.37±3.33⁎ 112.52±3.28⁎ 11.7±0.53⁎ 1.64±0.17⁎
(15.6±1.04)⁎ (18.47±1.95)⁎ (29.39±2.24)⁎ (3.06±0.7)⁎ (0.42±0.02)⁎
3-NP+quercetin 99.11±10.25† 91.56±1.05† 126.96±3.25† 16.96±0.96† 2.7±0.1†
(38.91±2.08)† (36.0±2.33)† (49.86±3.76)† (6.47±1.38)† (1.05±0.12)†
Values in parenthesis are normalized to citrate synthase activity. All values are expressed as mean±SEM; n=6/group.
⁎ Signiﬁcantly different from control group (pb0.05).
† Signiﬁcantly different from 3-NP treated group (pb0.05).
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Twentymicron thick frozen sections of the brain were dried for 30 min,
activated in PBS at 37 °C for 10 min and then incubated with reaction
mixture containing 0.3 M NBT, 0.05 M phosphate buffer, pH7.4, and
0.05 M sodium succinate at 37 °C in dark for 30 min. At the end of the
reaction, sections were extensively washed with the reaction buffer,
examined under the microscope and photographed.
Animals for histology were perfused transcardially with cold sa-
line followed by phosphate buffered 4% paraformaldehyde. The brains
were then post-ﬁxed overnight in 4% paraformaldehyde and later
brain sections were processed for routine hematoxylin and eosin
staining [40].2.8. Statistical analysis
All values are expressed as mean±standard error of mean (SEM)
of six animals per group. Data was analyzed using one way analysis
of variance (ANOVA) followed by Newman–Keuls test for multiple
pair-wise comparisons between the various treated groups using
SPSS 14 software. Values with pb0.05 were considered as statistically
signiﬁcant.Fig. 1. Effect of quercetin supplementation on SDH histochemical staining in frozen brain sec
at a magniﬁcation of 40×. Control sections show dense staining for normal SDH functioning
alone shows SDH functioning similar to that of control animals (B & II). SDH functioning w
showing improved SDH functioning (D & IV) (scale bar—40 μm).3. Results
3.1. Effect of quercetin on mitochondrial electron transport chain
enzymes, MTT reduction and mitochondrial swelling
Activities of mitochondrial electron transport chain (ETC) enzymes
were found to be signiﬁcantly inhibited by 3-NP administration
(Table 1). NADH dehydrogenase activity was inhibited by 45.01% in
3-NP treated animals as compared to control animals. The activity was
increased by 39.4% on quercetin supplementation to 3-NP treated
animals. Activity of succinate dehydrogenase (complex-II) was found
to be signiﬁcantly lowered by 51.64% in 3-NP treated group as com-
pared to control group. Supplementation with quercetin increased
complex-II activity by 22.05% in 3-NP treated animals. Histochemical
staining for SDH activity revealed a signiﬁcant decrease of the enzyme
reaction in the striatum of 3-NP treated animals (Fig. 1, C & III) as com-
pared to the control animals (Fig. 1, A & I). Quercetin supplementation
alone had SDH staining comparable to that of control striatal tissue
section (Fig. 1, B & II). The SDH staining recovered in brain sections on
quercetin supplementation to 3-NP treated animals (Fig. 1, D & IV).
Activity of terminal enzyme of mitochondrial ETC, cytochrome oxidase
was inhibited by 30.79% in 3-NP treated group as compared to controltions of 3-NP treated rats. Frozen brain sections were visualized under light microscope
(A & I). Histological appearance of striatal tissue from rats supplemented with quercetin
as compromised in 3-NP induced rats (C & III). Quercetin+3-NP administered groups
Fig. 2. Effect of quercetin supplementation on mitochondrial swelling in 3-NP treated
rats. Values are expressed as mean±SEM; n=6/group. * Signiﬁcantly different from
control group (pb0.05), † signiﬁcantly different from 3-NP treated group (pb0.05).
Table 3
Effect of quercetin administration on lipid peroxidation, superoxide dismutase and cata-
lase activity in mitochondria isolated from striatum of 3-NP treated rats.
Lipid peroxidation
(nmol MDA/mg
protein)
Superoxide
dismutase
(Units/mg
protein)
Catalase (μmol of H2O2
decomposed/min/mg
protein)
Control 4.09±0.37 4.42±0.21 2.07±0.17
Quercetin 4.21±0.48 3.81±0.13 1.69±0.06
3-NP 7.91±0.82⁎ 2.99±0.1⁎ 0.96±0.03⁎
3-NP+quercetin 5.93±0.31† 3.51±0.07† 1.34±0.11†
Values are expressed as mean±SEM; n=6.
⁎ Signiﬁcantly different from control group (pb0.05).
† Signiﬁcantly different from 3-NP treated group (pb0.05).
425R. Sandhir, A. Mehrotra / Biochimica et Biophysica Acta 1832 (2013) 421–430group. The activity was increased by 11.37% in 3-NP treated animals
supplemented with quercetin. Activity of mitochondrial F1–F0 synthase
(complex-V) was assessed by hydrolysis of ATP to ADP and was found
to be inhibited by 33.86% in 3-NP treated group as compared to control
group. On quercetin supplementation, the activity was increased by
31.01% in 3-NP treated animals. Mitochondrial functioning was also
assayed using MTT reduction (Table 1). MTT reduction was found to
be signiﬁcantly inhibited by 69.96% in 3-NP treated animals as com-
pared to control animals which was increased by 39.25% in
3-NP+quercetin co-supplemented animals. The perturbed activity of
ETC enzymes led to the increasedmitochondrial swelling in 3-NP treat-
ed animals which on quercetin supplementation was found to be
lowered (Fig. 2). The data in Table 2 depicts levels of ATP and ADP in
striatum following 3-NP and quercetin administration. It is clear from
the data that the compromised ETC components following 3-NP admin-
istration resulted in reduced levels of ATP with a concomitant increase
in ADP levels thereby lowering the ATP/ADP ratio. The effect was re-
versed on quercetin administration and the ATP/ADP ratio was restored
to near controls.3.2. Effect of quercetin on mitochondrial lipid peroxidation, superoxide
dismutase and catalase activity
The data for lipid peroxidation, activity of superoxide dismutase and
catalase in mitochondria isolated from striatum are depicted in Table 3.
Lipid peroxidation was signiﬁcantly increased (54%) in 3-NP treated as
compared to controls. Quercetin supplementation to 3-NP treated
animals lowered mitochondrial lipid peroxides by 38.22% as compared
to 3-NP group. The activity of superoxide dismutase (SOD) was
inhibited by 32.84% in 3-NP treated animals as compared to control
animals. However, quercetin supplementation signiﬁcantly increased
SOD activity by 14.73% in 3-NP animals. Catalase activity was found
to be signiﬁcantly inhibited by 53.48% in 3-NP treated animals as
compared to control animals. Quercetin supplementation resulted in a
signiﬁcant increase in catalase activity by 28.6% in 3-NP treated animals.Table 2
Effect of quercetin administration on adenine nucleotides in striatum of 3-NP treated
rats.
ATP
(nmol/mg protein)
ADP
(nmol/mg protein)
ATP/ADP
ratio
Control 9.15±1.41 4.24±0.39 2.16
Quercetin 10.01±1.29 4.87±0.73 2.07
3-NP 4.83±1.47⁎ 7.87±0.42⁎ 0.61
3-NP+quercetin 8.81±1.06† 4.94±0.38† 1.78
Values are expressed as mean±SEM; n=6.
⁎ Signiﬁcantly different from control group (pb0.05).
† Signiﬁcantly different from 3-NP treated group (pb0.05).3.3. Effect of quercetin on mitochondrial thiols
One of the most important antioxidant present in mitochondria is
thiol and its levels were found to be compromised in mitochondria iso-
lated from the striatum of 3-NP treated animals (Fig. 3). Total thiol
levels were found to be signiﬁcantly reduced by 54.22% in 3-NP treated
animals as compared to control animals. Quercetin supplementation
resulted in increased levels of total thiols (37.46%) in 3-NP treated ani-
mals. A signiﬁcant decrease in lowmolecular weight (51.39%) and pro-
tein thiols (55.03%) was observed in 3-NP treated animals as compared
to controls. Quercetin supplementation signiﬁcantly increased the low
molecular weight and protein thiols by 34.52% and 38.32% respectively
in 3-NP treated animals.
3.4. Effect of quercetin on neurobehavioral deﬁcits
3.4.1. Locomotor activity
The locomotor activity was assessed in terms of photo beam counts
for duration of 180 s using actophotometer (Fig. 4). On day 0, animals in
all the four groups had an average count of 166.5. Onday 1, the numbers
of counts for 3-NP treated animals fell to an average of 125, suggesting a
signiﬁcant impairment in locomotor functions. However, quercetin
supplementation to 3-NP treated animals increased the average
number of counts to 140. This trend of decline in locomotor functions
in 3-NP treated animals was followed for days 7, 14 and 21 following
3-NP treatment with an average of 70, 51 and 80 counts respectively.
Quercetin supplementation was able to signiﬁcantly improved locomo-
tor functions by recording an average of 134, 145 and 150 counts
respectively for days 7, 14 and 21 in 3-NP+quercetin animals.Fig. 3. Effect of quercetin supplementation on mitochondrial total, low molecular weight
(LMW) and protein thiols in mitochondria isolated from striatum of 3-NP treated rats.
Values are expressed as mean±SEM; n=6/group. * Signiﬁcantly different from control
group (pb0.05), † signiﬁcantly different from 3-NP treated group (pb0.05).
Fig. 4. Effect of quercetin supplementation on locomotor functions assessed using
actophotometer in terms of number of counts of 3-NP treated animals. Values are
expressed as mean±SEM; n=6/group. * Signiﬁcantly different from control group
(pb0.05), † signiﬁcantly different from 3-NP treated group (pb0.05).
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Narrow beam walk test was used to assess hind-limb impairment,
wherein the time taken by the rats to walk across a narrow beam
with progressively decreasing width was recorded (Fig. 5A). The maxi-
mum time allowed to each animal for traversing the beam was 120 s.
On day 0, average time taken by animals in all the four groups was
5.75 s. On day 1 following 3-NP treatment, the average time recorded
by 3-NP treated animals increased to 12 s, indicating a signiﬁcantFig. 5. Effect of quercetin supplementation on narrow beamwalk test in terms of total time (
expressed as mean±SEM; n=6/group. * Signiﬁcantly different from control group (pb0.0impairment in hind-limb function. Quercetin supplemented animals
on the other hand took an average of 9 s. Hind-limb impairment
following 3-NP administration continued to affect the animals having
an average of 14, 82 and 32 s on days 7, 14 and 21 respectively. Animals
supplementedwith quercetinwere able tomaintain hind-limb function
and traversed the beam in less time by recording an average time of 12,
35 and 13 s respectively for days 7, 14 and 21 each, in 3-NP+quercetin
group. The results indicate that quercetin administration was effective
in improving motor impairments induced by 3-NP.
The average velocity to cross the beam and the number of paw slips
for rats in treated groups were also calculated (Fig. 5B & C). On day 0,
average velocity by animals in all the four groupswas 25 cm/s, whereas
the average number of paw slips was 0.125. On day 1, 3-NP treated
animals recorded an average velocity of 13 cm/s and the average
number of paw slips increased to 1.25. However, quercetin supplemen-
tation to 3-NP treated animals increased the average velocity to 17 cm/s
and the average number of paw slips was 0.6. Average velocity further
decreased to 11 and 2 cm/s on days 7 and 14 with an increase in aver-
age number of paw slips to 2.1 and 7.3 respectively. But later on day 21,
average velocity increased to 5 cm/s and average paw slips to 2.25 in
3-NP treated animals. Quercetin supplementation was able to maintain
the average velocity to 12 and 6 cm/s and the average number of paw
slips to 0.7 and 0.6 on days 7 and 14, which were further signiﬁcantly
increased to 11.5 cm/s with a decrease in average number of paw
slips to just 0.5 in 3-NP+quercetin animals.
3.4.3. Effect of quercetin on footprint analysis
Paw slips are interpreted as a sign of abnormal gait. To further con-
ﬁrm abnormalities in treated rats, a footprint analysis was performed
daily from day 0 through day 21 (Fig. 6). Animals in all the groupsA), average velocity (B) and number of paw slips (C) of 3-NP treated animals. Values are
5), † signiﬁcantly different from 3-NP treated group (pb0.05).
Fig. 6. Effect of quercetin supplementation on footprint test for gait analysis by control (A), quercetin (B), 3-NP (C) and 3-NP+quercetin (D) treated animals.
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length for both left and right paws. Out of six parameters that were
analyzed only the stride length for both, left and right paws was signif-
icantly affected in the animals that received 3-NP+quercetin supple-
mentation in comparison to 3-NP treated animals (data not shown).
However, the footprint length and footprint breadth for both left
and right paws remained unaffected (data not shown). An additional
measurement of walking pattern is the paws overlap which was
calculated as the minimum distance (in cm) between left and right
paws overlap (Fig. 7). The rationale of this analysis lies on the fact that
rodents while walking usually tend to step their hind paw in the same
place previously occupied by their front paw. Quantifying this aspect
of themotor behavior could then be considered as ameasure of locomo-
tor ability. On day 0, the average distance of left paw for animals in all
the four groups was 0.75 cm, whereas for right paw it was 0.9 cm. On
days 7, 14 and 21, 3-NP treated animals recorded a signiﬁcant increase
in average distance of left paw overlap of 0.9, 0.6 and 0.6 cm respective-
ly. Average overlap distance in right paw for days 7, 14 and 21 was
signiﬁcantly found to be 1.1, 0.66 and 0.61 cm respectively. However,
quercetin supplementation in 3-NP+quercetin animals maintained
an overall average distance in left and right paws overlap between
0.25 and 0.45 cm for the entire duration of 21 days, suggesting the
ability of quercetin in preventing gait abnormalities observed in 3-NP
induced HD.Fig. 7. Effect of quercetin supplementation on gait analysis in terms of left paw (A) and
right paws (B) overlap of 3-NP treated animals. Values are expressed as mean±SEM;
n=6/group. * Signiﬁcantly different from control group (pb0.05), † signiﬁcantly different
from 3-NP treated group (pb0.05).3.5. Effect of quercetin on histopathological changes
Histopathological changes in the striatum of control and 3-NP
treated animals are depicted in Fig. 8. The striatum of control rats
shows normal morphology. Quercetin supplementation to rats alone
exhibited normal appearance of striatum as similar to that of control
rats. Striatal sections of rats treated with 3-NP exhibited irregular
damaged cells with condensed and pyknotic nuclei (Fig. 8C). Querce-
tin treatment to 3-NP animals resulted in modulation of the abnor-
malities in the striatal histopathology near to normal (Fig. 8D).4. Discussion
Defects in mitochondrial functions have been proposed to contrib-
ute substantially to most of the neurodegenerative disorders including
HD. The activity of mitochondrial complexes-I, II, IV and F1F0 synthase
Fig. 8. Effect of quercetin supplementation on histopathological alterations in striatum of control and 3-NP treated rats. Sections were visualized under light microscope at a mag-
niﬁcation of 40×. (A) Control rats showing normal striatal histology. (B) Histological appearance of striatal tissue from rats supplemented with quercetin alone shows normal cell
nuclei similar to that of control animals. (C) 3-NP induced rats showing damaged and condensed pyknotic nuclei in striatum (PN). (D) Striatum of quercetin+3-NP administered
groups showing lesser number of pyknotic nuclei (scale bar—100 μm).
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to bioenergetic failure in terms of reduced ATP levels andATP/ADP ratio.
This inhibition in activities might be an effect of hydroxyl radicals
generated due to 3-NP mediated SDH inhibition [41]. In addition, MTT
reduction (a marker of mitochondrial functioning) was markedly
reduced in the striatum of 3-NP treated animals. Mitochondrial
complex-II has been reported to, at least partly, involved in MTT reduc-
tion by intact astrocytes and neurons, conﬁrming inhibition of SDH by
3-NP [42]. This metabolic defect imposed by 3-NP treatment might be
closely associated with ATP depletion, mitochondrial swelling, loss of
ionic gradients, and alterations in mitochondrial membrane structure
and function [43]. Preferential decrease of SDH activity in the lesion
area of 3-NP treated animals in the histochemical assay corroborates
the earlier observations [39] and is in accordance with the biochemical
ﬁndings in the present study showing inhibition in SDH activity. Quer-
cetin supplementation to 3-NP treated animals restored SDH staining
in the striatum as compared to 3-NP treated animals. We also found
an increase in mitochondrial swelling on 3-NP administration which
might be attributed to increased production of harmful ROS. Quercetin
supplementation to 3-NP treated animals restored the normal function-
ing of ETC enzymes along with a signiﬁcant increase in F1–F0 synthase
activity, restoration of ATP levels and prevention of mitochondrial
swelling. The beneﬁcial effect of quercetin might be attributed to
antioxidant activity of this ﬂavonoid. Complex I and cytochrome c are
suggested to bemolecular targets of quercetin action thereby inhibiting
H2O2 production [44]. Quercetin has been shown to prevent the open-
ing of MPT pore thereby preventing mitochondrial swelling [19]. Quer-
cetin has been reported to bind to a variety of cytosolic proteins and
accumulates in lipid compartments (i.e., membranes), suggesting that,
hydrophobic compartments such as mitochondria, in which heme-
containing proteins are largely expressed, may represent a site of
preferential accumulation of the ﬂavonoid [45]. Since, mitochondria
represent a critical source of ROS and their ability to accumulate querce-
tin may be functional for protection of mitochondrial function andintegrity. Quercetin has recently been reported to be most efﬁcient in
protecting against indomethacin-induced mitochondrial dysfunctions
and this could be due to its ability to enter cells and accumulate in
mitochondria [46]. Furthermore, quercetin supplementation has also
been shown to protect mitochondrial integrity and size along with
mitochondrial functions by controlling succinate dehydrogenase and
NADH oxidase activities [47].
Increased oxidative stress is attributed to alterations in antioxidant
defense system which includes lipid peroxidation and antioxidant
enzymes. One of the most abundant products of lipid peroxidation is
MDA. The values of mitochondrial MDA levels in 3-NP exposed animals
were found to be signiﬁcantly higher. Quercetin supplementation to
3-NP treated animals was able to signiﬁcantly lower lipid peroxide
levels. These ﬁndings are supported by a study in which, protective
effect of quercetin is correlated with the capacity of this ﬂavonoid to
detoxify H2O2 and thereby effectively blocking MDA formation in the
brain [48]. Also, multiple methylation of the hydroxyl groups present
in quercetin increases lipophilic nature of the molecule, thereby in-
creasing availability of the ﬂavonoid in mitochondrial membrane and
preventing lipid peroxidation, thus enhancing the pharmacological po-
tential of this ﬂavonoid against such pathological processes [49].
MnSOD is also regarded as a critical component of the enzymatic anti-
oxidant defense system and in the present study SOD activity was
found to be signiﬁcantly lowered in 3-NP treated animals. This could
be due to increased generation of superoxide radicals, leading to
decrease in the activity of MnSOD. 3-NP administration also resulted
in a signiﬁcant decrease in catalase activity. However, quercetin supple-
mentation to 3-NP induced HD animals for 21 days signiﬁcantly
improved the levels of MnSOD and catalase, suggesting that it is an ef-
fective mechanism in ameliorating mitochondrial oxidative stress. In
contrast, quercetinpossesses bothpro- and anti-oxidantproperties [50],
and it was therefore hypothesized that quercetin effects on MnSOD
activity may be due to changes in expression of the MnSOD gene [51].
Quercetin was shown to be a potent inhibitor of H2O2 production,
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al inhibitors such as rotenone and antimycin A [45]. Quercetin has also
been shown to prevent oxidative nuclear and mitochondrial DNA
damage [52].
In biological systems, thiols play a central role in coordinating the
antioxidant defense network by their ability to act as reducing agents
[53]. Non-enzymatic antioxidant, GSH constitutes the ﬁrst line of
defense against free radicals. Mitochondrial total (TSH), low molecular
weight (such as GSH) and protein thiols (PSH) were found to be signif-
icantly lowered in 3-NP treated animals. The decrease in TSH content in
3-NP induced HD animals might be due to a reduction in GSH levels, as
it has been demonstrated that GSH oxidation causes extensive redox
changes to mitochondrial thiol proteins [54]. The probability that a
cell will undergo apoptosis and ensue mitochondrial swelling is in
part dictated by the cellular redox potential, which is mainly deter-
mined by the reduction and oxidation of mitochondrial thiol residues
[55]. Thus a decrease in mitochondrial thiol content makes a cell more
susceptible to apoptosis causing osmotic swelling of mitochondria,
which may be the case in 3-NP induced HD. Evidence of decreased
thiol level in 3-NP treated animals suggests that endogenous antioxi-
dants may play a role in protecting against 3-NP induced oxidation
[56]. Supplementation with quercetin to 3-NP treated animals was
found to be effective in preventing decrease in mitochondrial thiols
suggesting direct neutralization of ROS by quercetin.
Neurobehavioral impairment is a characteristic symptom of striatal
cell loss and is found in neurodegenerative disorders such as HD.
Increased oxidative stress and mitochondrial dysfunctions following
3-NP administration can result in poor cognitive and motor functions
[43]. Our results showed consistent decrease in locomotor activity,
increased time taken to cross the narrow beam and increased paw
slipswhich resulted in decreased average velocity of 3-NP administered
animals. Footprint analysis for gait abnormalities showed reduced step
length and signiﬁcant decrease in stride length in 3-NP treated animals
hence, clearly establishing gait abnormalities in the 3-NP model of HD.
Among the other parameters of gait abnormalities, stride length has
been used as a reliable marker of basal ganglia dysfunction leading to
motor abnormalities [57]. In addition, the analysis of the beam test
conﬁrmed that a progressive difﬁculty in accomplishing a task of
increasing complexity could be due to 3-NP induced development of
gait abnormalities. Quercetin supplementation to 3-NP administered
animals signiﬁcantly improved motor functions and gait in animals,
which reﬂects the ability of quercetin to prevent 3-NP-induced mito-
chondrial dysfunctions.
3-NP-induced histopathological ﬁndings have been well character-
ized in a number of previous reports [58]. In our study, 3-NP-induced
rats exhibited irregular damaged cells with condensed and pyknotic
nuclei in striatum, which replicates the histological alterations similar
to that in humanHD [59]. These histological changes could be attributed
to increased oxidative stress following 3-NP administration. Quercetin
has shown protective effect by decreasing neuronal death and reducing
reactive astrogliosis after ischemia–reperfusion injury, suggesting that
quercetin should provide therapeutic beneﬁts for suppression of
inﬂammatory-related neuronal injury in neurodegenerative diseases
[60]. The neuroprotective effect of quercetin was observed on animals
treated with 3-NP showing only milder degenerative changes com-
pared to 3-NP treated animals. Quercetin improved respiratory chain
functions, antioxidant status and neurobehavioral functions in 3-NP
treated animals whichmay be due to the presence of phenolic hydroxyl
groups, which act as electron donors and are responsible for free radical
scavenging activity of quercetin. In particular, the catechol structure
which possesses two hydroxyl groups at neighboring positions is re-
markably superior to other dispositions in electron donating ability.
The antioxidant activity of quercetin can also be explained by their che-
lating action and the catechol group is recognized to contribute directly
to the chelating action of quercetin, reﬂecting its natural capability as a
therapeutic agent. Furthermore, the beneﬁcial effect of quercetin onmitochondrial functionsmight involve increasedmitochondrial biogen-
esis through regulation of sirtuins (SIRT1) or peroxisome proliferator-
activated receptor gamma co-activator (PGC-1) [61,62].
5. Conclusions
In conclusion, our results reveal that quercetin prevents mitochon-
drial dysfunctions, oxidative stress along with motor deﬁcits in 3-NP
induced HD. Thus, suggesting the potential of quercetin as an antioxi-
dant which can be engaged in themanagement of HD and other neuro-
degenerative disorders wherein mitochondrial functions are perturbed.
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